CR9908A - Metodo para la anticoncepcion hormonal preventiva bajo demanda - Google Patents

Metodo para la anticoncepcion hormonal preventiva bajo demanda

Info

Publication number
CR9908A
CR9908A CR9908A CR9908A CR9908A CR 9908 A CR9908 A CR 9908A CR 9908 A CR9908 A CR 9908A CR 9908 A CR9908 A CR 9908A CR 9908 A CR9908 A CR 9908A
Authority
CR
Costa Rica
Prior art keywords
preventive
under demand
demand
hormonal anti
conception under
Prior art date
Application number
CR9908A
Other languages
English (en)
Inventor
Karin Schimidt-Gollwitzer
Gunter Stock
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CR9908A publication Critical patent/CR9908A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se relaciona con un metodo de anticoncepcion hormonal femenina controlada bajo demanda que comprende administrar una preparacion farmaceutica que comprende al menos un gestageno por via transdermica, bajo demanda y en una sola ocasion, en anticipacion del encuentro sexual.
CR9908A 2005-10-19 2008-04-21 Metodo para la anticoncepcion hormonal preventiva bajo demanda CR9908A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005050729A DE102005050729A1 (de) 2005-10-19 2005-10-19 Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption

Publications (1)

Publication Number Publication Date
CR9908A true CR9908A (es) 2008-05-21

Family

ID=37762565

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9908A CR9908A (es) 2005-10-19 2008-04-21 Metodo para la anticoncepcion hormonal preventiva bajo demanda

Country Status (13)

Country Link
US (3) US20070111976A1 (es)
EP (1) EP1937275A1 (es)
JP (2) JP2009512658A (es)
KR (1) KR20080056774A (es)
CN (1) CN101340915A (es)
BR (1) BRPI0617683A2 (es)
CA (1) CA2626567C (es)
CR (1) CR9908A (es)
DE (1) DE102005050729A1 (es)
EC (1) ECSP088390A (es)
GT (1) GT200800038A (es)
HN (1) HN2008000621A (es)
WO (1) WO2007045513A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201070715A1 (ru) * 2007-12-20 2011-02-28 Тева Вимен'С Хелс, Инк. Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции
EP3106167A1 (en) 2009-04-14 2016-12-21 Laboratoire HRA Pharma Method for on-demand contraception
WO2010119030A1 (en) * 2009-04-14 2010-10-21 Ulmann Andre Method for on-demand contraception using levonorgestrel or norgestrel
DE102010040299A1 (de) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2922552A1 (de) 2012-11-22 2015-09-30 Bayer Pharma Aktiengesellschaft Verwendung und anwendungsregime einer pharmazeutischen zusammensetzung enthaltend levonorgestrel und einen cox-inhibitor zur bedarfsweisen ("on-demand") kontrazeption
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2913085A1 (en) 2013-05-23 2014-11-27 Bernhard Lindenthal Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
DE4229820C2 (de) * 1992-09-07 1998-12-03 Jenapharm Gmbh Pharmazeutische Zubereitung auf Gestagen-Basis
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
EP0787002B1 (de) * 1994-10-24 2006-12-13 Schering Aktiengesellschaft Kompetitive progesteronantagonisten zur bedarfsorientierten weiblichen fertilitätskontrolle
EP1605949A2 (en) * 1999-08-31 2005-12-21 Schering Aktiengesellschaft Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
AU2003245252A1 (en) * 2002-04-30 2003-11-17 Fmc Corporation Carrageenan based antimicrobial compositions
KR101168449B1 (ko) * 2003-12-12 2012-07-25 바이엘 파마 악티엔게젤샤프트 침투 증진인자가 필요없는 호르몬의 경피 전달계
UA89766C2 (en) * 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene

Also Published As

Publication number Publication date
HN2008000621A (es) 2011-07-22
US20070111976A1 (en) 2007-05-17
GT200800038A (es) 2009-04-01
CA2626567A1 (en) 2007-04-26
JP2014001239A (ja) 2014-01-09
CA2626567C (en) 2013-12-03
KR20080056774A (ko) 2008-06-23
JP2009512658A (ja) 2009-03-26
WO2007045513A1 (de) 2007-04-26
CN101340915A (zh) 2009-01-07
BRPI0617683A2 (pt) 2011-08-02
EP1937275A1 (de) 2008-07-02
US20080311180A1 (en) 2008-12-18
DE102005050729A1 (de) 2007-04-26
ECSP088390A (es) 2008-05-30
US20130089574A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
CR9908A (es) Metodo para la anticoncepcion hormonal preventiva bajo demanda
CR7022A (es) Productos esteroides hormonales y metodos para su preparacion
HN2001000266A (es) Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
CL2008003827A1 (es) Composicion para tabletas de desintegracion oral que comprende al menos una droga ( temazepam), 0,5-3% de un polimero aglutinanete para odt, un alcohol de azucar y/o sacarido, y un desintegrante; metodo para prepararla; util para tratar una enfermedad o condicion como un trastorno del sueño en pacientes con disfagia..
AR032204A1 (es) Complejos de inclusion de ciclodextrina-drospirenona
AR078247A1 (es) Vacuna de pcsk9
ECSP088123A (es) Anticoncepcion oral con trimegestona
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
BR122019021238B8 (pt) uso de um inibidor do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
CR10259A (es) Metodos para la prevencion y tratamiento de condiciones que surgen de deficiencia de estrogeno local
ECSP088504A (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos
CL2011003113A1 (es) Composicion adyuvante acuosa que comprende un agonista de tlr-4 y una saponina y un agente de isotonicidad no ionico; proceso para la preparacion de una composicion inmunogenica.
MX343358B (es) Tabletas de acetato de ulipristal.
AR048833A1 (es) Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos
AR054525A1 (es) Composiciones y metodos para eltratamiento de sintomas relacionados con el ciclo
DOP2006000223A (es) Procedimiento para la produccion de una preparacion farmacéutica monofasica para la terapia oral de la hemorragia uterina disfuncional.
CL2012001671A1 (es) Compuestos derivados de (metilsulfonil)-etil-bencenoisoindolina; composicion farmaceutica que los comprende, uso en el tratamiento del cancer, dolor, trastornos del snc, enfermedades dermatologicas, entre otras.
CL2012003105A1 (es) Bacteria comensal geneticamente diseñada, del tracto genital femenino que expresa un agente anti espermatozoide; composicion que comprende dicha bacteria; uso de dicha composicion para la reduccion de la incidencia de embarazo en una poblacion femenina; dispositivo de insercion intravaginal.
PL1845957T3 (pl) Sposób uzyskiwania ekstraktu leku zawierającego hydroksystylben
AR049065A1 (es) Forma de administracion para la contracepcion hormonal
WO2009013405A8 (fr) Controle de la fertilite d'un etre humain de sexe masculin via spata16
PE20090805A1 (es) COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL
CO6450623A2 (es) Parasiticidas sanguineos
ES2574999T3 (es) Método para la contracepción a demanda usando levonorgestrel o norgestrel

Legal Events

Date Code Title Description
FC Refusal